Clinical Trial Update: Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption [Phase 2]

View source ↗

Summary

Phase 2 trial update describing immunotherapy with baricitinib and sirolimus, alone or in combination, to control HIV-1 replication after antiretroviral treatme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Olumiant (baricitinib)
• Rapamune (sirolimus)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: HIV-1-infection | Phase 2 | Status: NOT_YET_RECRUITING